BRAF and neoplasm: Based on the levels of unrecombined and recombined Braf CA/+ alleles detected in each sample, we estimated (see Methods) that the fraction of DNA that was tumor-derived in each sample was 19%, 55%, and 36%, for tumors 1, 2, and 3, respectively, in Fig. 1d,e.